保障战略资源安全，挺进产业升级前沿，是经济大省必须扛起的责任。在关系国计民生的生物医药领 域，山东如何"挑大梁"？答案，或许就铭刻在一支支小小的药瓶上。 血液制品，是国家重要的战略储备资源，在临床救治中发挥着不可替代的关键作用，无论是应对突发公 共卫生事件、抢救危重患者，还是在疫情防控等关键时期，它都是保障生命安全的重要支撑。它的供给 安全与技术创新，直接关乎重大疾病救治、公共卫生应急与国家安全体系。山东泰邦生物制品有限公司 二十余年如一日，将"为人类健康造好药"的使命，锻造成了一把破解资源瓶颈、攻坚核心技术的"硬 核"钥匙。作为国家定点、山东省唯一的集科研、生产、经营于一体的血液制品专业化企业，它不仅是 产业创新的样本，更是观察山东以新质生产力重塑传统优势产业、在高质量发展中"走在前、开新局"的 生动切片。 始于国需，成于"至信"：一根融入文化基因的质量脊梁 通讯员席智赢 拓展纵深，筑牢根基：一张覆盖全国的产业与责任网络 企业的竞争力，源于全产业链的深度掌控与市场格局的广度开拓。 在前端，泰邦生物在山东、河北两省依法设立16家单采血浆站，全部实现智能化、规范化管理，从源头 夯实了战略资源的供给基础。 泰邦生 ...

Summary of Blood Products Industry Conference Call Industry Overview - The blood products industry is experiencing a recovery in 2025, but faces challenges such as supply-demand imbalance and pricing pressure due to increased plasma collection exceeding demand growth [1][3][15] - The market for albumin is under pressure, with public hospitals maintaining stable channels while external channels face intense competition [1][3] Key Points Supply and Demand Dynamics - Plasma collection growth exceeded 15% in 2023 and 2024, leading to an oversupply of albumin in early 2025 [2] - Demand for albumin remains stable at 5% to 8% annually, contrasting with double-digit supply growth [3] Pricing Trends - The Guangdong province's centralized procurement has led to significant price reductions among small enterprises, while larger companies maintain relatively stable prices [1][7][9] - The price for low-end imported products remains around 350 RMB, while high-end brands have stable pricing [1][10] Market Segmentation - The blood products market shows a clear polarization, with large companies like Shanghai RAAS and Zhongsheng Group maintaining stable prices in public hospitals, while smaller companies struggle to maintain pricing in competitive external channels [6][10] Competitive Landscape - New entrants like HeYuan Bio's recombinant albumin face challenges due to high pricing and limited supply, while competitors like Anruite have a more mature supply chain and are expected to enter the market soon [17][19] - The competition among 10% albumin products is expected to intensify, with adjustments in pricing strategies to cover hospital markets [12][13] Regulatory and Export Considerations - The Chinese blood products export market is gaining attention, with companies like Zhongsen Group and Shanghai Xinxing Group actively participating in overseas markets [21] - Future regulations and quality standards will play a crucial role in determining the success of companies in international markets [24] Future Trends - The industry is expected to consolidate, with potential mergers and acquisitions among smaller companies to achieve greater market concentration [22] - The introduction of recombinant products may reshape the competitive landscape, potentially lowering prices and increasing market share for domestic products [25][26] Challenges Ahead - The industry faces challenges such as regulatory hurdles, pricing pressures, and the need for new indications to avoid market saturation [14][16] - The impact of COVID-19 on market dynamics is still being assessed, with a focus on long-term growth strategies [15] Conclusion - The blood products industry is at a critical juncture, balancing between recovery and the need for strategic adjustments to navigate pricing pressures and competitive dynamics. The focus on regulatory compliance and market expansion will be essential for future growth and stability.

Summary of the Conference Call for Boya Biological Company Overview - **Company**: Boya Biological - **Focus**: Blood products, with a strategic emphasis on expanding production and market presence Key Points and Arguments Financial Performance - **Total Revenue**: 1.735 billion CNY, a year-on-year decrease primarily due to the divestiture of Tianan Pharmaceutical and Fudan Pharmaceutical [3] - **Blood Products Revenue**: 1.514 billion CNY, a year-on-year increase of 4.32%, driven by significant sales growth in prothrombin complex and factor VIII [3] - **Operating Profit**: 397 million CNY, a year-on-year increase of 67.18%, attributed to a lower base from the previous year [3] - **Return on Equity**: Increased by 2.08 percentage points to 5.36% [3] Business Expansion and Acquisitions - **Acquisition**: Successfully acquired 100% of the shares of Roche in Hong Kong, adding a production license and four plasma collection stations, bringing the total to 21 stations across seven provinces [5] - **Plasma Collection**: Achieved 630.6 tons of plasma collection, a year-on-year increase of 10.4%, with the main collection unit growing by 11.7%, surpassing industry averages [5] Product Development and Market Strategy - **Product Sales**: Strong performance in fibrinogen, with PCC and factor VIII exceeding sales targets, and PCC holding the third-largest market share [6] - **International Expansion**: Registered a new immunoglobulin product in Pakistan, indicating a strategic move towards international markets [6] Major Projects - **Smart Factory Project**: Progressing as planned, with the main structure completed and equipment installation ongoing, expected to commence production by the end of 2025, with financial impacts anticipated post-2027 [7][15] Industry Dynamics - **Supply and Demand**: Industry supply pressures have eased, with balanced demand for protein products, although competition for factor products may intensify [10] - **Collective Procurement Strategy**: Actively participating in Guangdong's collective procurement, monitoring policy changes closely [10] Future Projections - **Plasma Collection Goals for 2025**: Expected to exceed 700 tons, with a growth rate of over 10% [3][17] - **New Product Launches**: Anticipated rapid market uptake for new products expected to launch in Q3 2025 [9] Regulatory and Market Considerations - **Regulatory Changes**: Ongoing discussions regarding potential revisions to blood product management regulations, which could significantly impact the industry [20] - **Market Strategy Adjustments**: Focus on regional market penetration, particularly in East China, to optimize existing production capacity [21] Integration and Collaboration - **Sales Team Integration**: Ongoing integration of sales teams from Roche and Boya, aiming for enhanced market coverage and synergy [19] - **Technical Collaborations**: Engaging in technical cooperation with Central Asian countries to expand market reach and capabilities [17] Investment and Future Outlook - **Investment Plans**: Continued focus on core business and strategic acquisitions to enhance market position and operational efficiency [24] - **Long-term Growth Strategy**: Emphasis on technological innovation and market competitiveness to ensure sustainable growth [26] Additional Important Insights - **Market Potential in New Regions**: Significant growth potential identified in Anhui and Inner Mongolia, with strategic plans to address local concerns and enhance operational trust [22] - **Impact of Economic Conditions**: Despite macroeconomic pressures, the company has maintained a strong performance trajectory [11]